Febuxostat Tablets
DEPT OF DEFENSE.DEFENSE LOGISTICS AGENCY.TROOP SUPPORT MEDICAL.DLA TROOP SUPPORT · Response deadline: Thu, 15 Oct 2026
What the government is buying
The Defense Logistics Agency (DLA) Troop Support is soliciting offers for febuxostat tablets, a prescription medication used to treat chronic hyperuricemia in patients with gout. Febuxostat works by inhibiting xanthine oxidase, the enzyme responsible for uric acid production. In military and federal healthcare settings, this pharmaceutical product supports the medical readiness of service members and eligible beneficiaries by managing a condition that can cause debilitating joint pain and mobility limitations.
As a DLA Troop Support medical procurement, this contract falls under the pharmaceutical prime vendor program or direct procurement framework that supplies medications to Military Treatment Facilities, VA hospitals, and other federal healthcare providers. The classification code 6505 confirms this is a drug and biological product procurement.
Key facts
| Attribute | Value |
|---|---|
| Agency | Defense Logistics Agency (DLA) Troop Support, Medical |
| Notice type | Solicitation |
| Solicitation number | SPE2D2-26-R-0012 |
| NAICS | 325412 — Pharmaceutical Preparation Manufacturing |
| Set-aside | None (full and open competition) |
| Response deadline | October 15, 2026, 3:00 PM EDT |
| Place of performance | Not specified in metadata; see the solicitation |
Who can bid
This solicitation is full and open competition with no set-aside restriction, meaning any responsible offeror—regardless of business size—may submit a bid. However, the NAICS code 325412 (Pharmaceutical Preparation Manufacturing) typically requires offerors to demonstrate:
- FDA registration and compliance: Active establishment registration, drug listing, and adherence to Current Good Manufacturing Practice (CGMP) regulations
- FDA approval for febuxostat: Either Abbreviated New Drug Application (ANDA) for generic versions or established supplier relationships with the applicable NDA/ANDA holder
- DHHS Office of Inspector General (OIG) certification: Required for pharmaceutical manufacturers and suppliers to federal healthcare programs
Eligible bidders include large pharmaceutical manufacturers, generic drug manufacturers with approved ANDAs, and potentially authorized distributors with manufacturing partnerships. Small manufacturers meeting these requirements should not be deterred by the absence of a small business set-aside; DLA medical solicitations prioritize technical capability and pricing competitiveness over size status.
How to put together a competitive bid
Pharmaceutical solicitations to DLA Troop Support are highly technical and price-sensitive. Focus on these elements:
Regulatory documentation: Assemble your FDA establishment registration, most recent inspection classification, drug listing files, and any FDA warning letters or resolution documents. DLA's Medical Supply Chain expects complete transparency on manufacturing sites and compliance history.
Technical proposal: See the solicitation for exact requirements, but typically include drug master file references, stability data, packaging configurations, shelf life, and National Drug Code (NDC) assignments. Highlight any advantages in delivery lead times or supply chain redundancy.
Pricing structure: DLA pharmaceutical awards are heavily price-driven. Analyze your active pharmaceutical ingredient (API) costs, tender manufacturing costs, and any economies of scale. Consider whether offering multiple National Stock Number (NSN) configurations or volume-tiered pricing strengthens your position.
Past performance: Document prior DLA, VA, or TriCare pharmaceutical contracts, especially for ULD (Uric Acid Lowering Drugs) or similar therapeutic categories. Reference any existing Pharmaceutical Prime Vendor (PPV) relationships.
Quality assurance: Describe your lot release testing, certificate of analysis protocols, and track-and-trace capabilities under the Drug Supply Chain Security Act (DSCSA).
Next steps
Read the full solicitation on SAM.gov using solicitation number SPE2D2-26-R-0012 to obtain the statement of work, deliverables schedule, evaluation criteria, and exact packaging/labeling requirements.
Note the deadline: Responses are due October 15, 2026, at 3:00 PM EDT—substantially short turnaround from the October 14, 2026 posting date, suggesting this may be a recompetition or urgent procurement.
Register in SAM and confirm your entity's active status and representations/certifications are current, including pharmaceutical-specific provisions.
Contact DLA Troop Support Medical promptly for any clarifications, given the compressed response timeline.
View the official notice on SAM.gov →